FDA Accepts Cue Biopharma's IND for CUE-102 in WT1-Expressing Cancers

Retrieved on: 2022-05-11 14:38:21

Tags for this article:

Click the tags to see associated articles and topics

FDA Accepts Cue Biopharma's IND for CUE-102 in WT1-Expressing Cancers. View article details on hiswai:

Excerpt

NEW YORK – Cue Biopharma said Wednesday that the US Food and Drug Administration has accepted its investigational new drug application to study ...

Article found on: www.precisiononcologynews.com